Applied BioCode Stock

Applied BioCode Revenue

The The revenue of Applied BioCode (6598.TW) as of Aug 15, 2026 is 475.20 M TWD. In the previous year, The revenue was 343.07 M TWD — a change of 38.52% (higher).

Revenue

475.20 MTWD

YoY

38.52%

Last updated:

In 2026, Applied BioCode's sales reached 475.20 M TWD, a 38.52% difference from the 343.07 M TWD sales recorded in the previous year.

Revenue has compounded at 27.1% per year over the past 12 years to 475.20 M TWD.

The Applied BioCode Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

REVENUE (M TWD)
GROSS MARGIN (%)
Date
REVENUE (M TWD)
GROSS MARGIN (%)
Jan 1, 2019
104.69 base
50.59 base
Jan 1, 2020
299.02 base
64.72 base
Jan 1, 2021
319.96 base
59.18 base
Jan 1, 2022
390.30 base
60.00 base
Jan 1, 2023
395.17 base
68.01 base
Jan 1, 2024
343.07 base
59.46 base
Jan 1, 2025
475.20 base
54.90 base
Jan 1, 2026 (e)
0.00 base
0.00 base
YEARREVENUE (M TWD)GROSS MARGIN (%)
2026 est --
2025 475.2054.90
2024 343.0759.46
2023 395.1768.01
2022 390.3060.00
2021 319.9659.18
2020 299.0264.72
2019 104.6950.59
2018 37.1545.05
2017 26.7633.32
2016 11.7641.62
2015 23.2526.84
2014 15.1917.95
2013 26.627.58
Access this data via the Eulerpool API

Applied BioCode Revenue

Applied BioCode Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
104.69 M TWD
-273.46 M TWD
-280.07 M TWD
Jan 1, 2020
299.02 M TWD
-99.16 M TWD
-103.50 M TWD
Jan 1, 2021
319.96 M TWD
-162.31 M TWD
-165.20 M TWD
Jan 1, 2022
390.30 M TWD
-181.93 M TWD
-184.73 M TWD
Jan 1, 2023
395.17 M TWD
-186.70 M TWD
-164.20 M TWD
Jan 1, 2024
343.07 M TWD
-277.67 M TWD
-260.81 M TWD
Jan 1, 2025
475.20 M TWD
-223.33 M TWD
-201.20 M TWD
Jan 1, 2026 (e)
0.00 TWD
0.00 TWD
0.00 TWD

Applied BioCode Margins

Applied BioCode stock margins

The Applied BioCode margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Applied BioCode. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Applied BioCode.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
50.59 %
-261.20 %
-267.52 %
Jan 1, 2020
64.72 %
-33.16 %
-34.61 %
Jan 1, 2021
59.18 %
-50.73 %
-51.63 %
Jan 1, 2022
60.00 %
-46.61 %
-47.33 %
Jan 1, 2023
68.01 %
-47.25 %
-41.55 %
Jan 1, 2024
59.46 %
-80.94 %
-76.02 %
Jan 1, 2025
54.90 %
-47.00 %
-42.34 %
Jan 1, 2026 (e)
54.90 %
0.00 %
0.00 %

Applied BioCode Stock analysis

What does Applied BioCode do? Applied BioCode Corp is a California-based company that focuses on the development and marketing of diagnostic instruments and tests. The company was founded in 2004 by an experienced management team and has since developed a number of groundbreaking technologies to improve the diagnosis of diseases such as cancer, infectious diseases, and autoimmune diseases. The business model of Applied BioCode Corp is based on the development of innovative diagnostic instruments and test systems based on proprietary technologies. The company has a strong partnership with a leading manufacturer of diagnostic automation systems, allowing a wide range of tests for various diseases to be offered. Applied BioCode Corp also works closely with leading research and development organizations to leverage the latest insights in the field of diagnostics. One of the divisions of Applied BioCode is molecular diagnostics, which is an essential component of modern medicine. Molecular diagnostics enables the detection of genetic changes and deviations related to diseases. Applied BioCode's technology allows for rapid and precise identification of pathogens in clinical samples such as blood, urine, and tissue samples. Another important area for Applied BioCode is infectious disease diagnostics. The company has developed a range of test systems based on a variety of infectious diseases such as influenza, tuberculosis, and sexually transmitted diseases such as chlamydia and gonorrhea. These tests can be performed individually or as a group to facilitate disease diagnosis and improve treatment. Applied BioCode also offers tests for the detection of oncological markers. These tests are crucial for the early detection of cancer and monitoring the treatment of cancer patients. Applied BioCode's technology enables rapid and precise identification of cancer cells in blood or tissue, which can improve the effectiveness of treatment. Another important product of Applied BioCode is the BioCode Analyzer, an automated diagnostic instrument. The BioCode Analyzer is a high-throughput system capable of performing multiple tests simultaneously. The analyzer is equipped with a disposable chip that allows for quick and easy diagnosis. This makes the BioCode Analyzer a powerful tool for laboratory automation, providing fast and accurate diagnosis for a variety of diseases. Applied BioCode is also dedicated to researching and developing new technologies. The company has an active pipeline of new products and technologies to further improve diagnostic accuracy and the number of feasible tests. Applied BioCode is also developing new applications for its technologies to improve the diagnosis and treatment of diseases in various ways. In summary, Applied BioCode Corp plays an important role in the field of diagnostic technology. The company has developed a wide range of innovative diagnostic tests and instruments that enable diseases to be quickly and accurately detected. With its strong partnership with leading diagnostic automation system manufacturers and research organizations, Applied BioCode will continue to stay at the forefront and improve diagnostic practice. Applied BioCode is one of the most popular companies on Eulerpool.

Revenue Details

Understanding Applied BioCode's Sales Figures

The sales figures of Applied BioCode originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Applied BioCode’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Applied BioCode's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Applied BioCode’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Applied BioCode stock

The revenue of Applied BioCode is 475.20 M TWD in 2026.

The revenue of Applied BioCode changed from 343.07 M TWD to 475.20 M TWD, representing a 38.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The revenue Applied BioCode since 2006 – with annual values, charts, and detailed analysis.

Revenue is the total value of all goods sold in a period. It is calculated by multiplying the quantity of each product sold by its selling price. Revenue does not include any costs (material costs, personnel costs, etc.), whereas net proceeds only deduct revenue reductions associated with the sale (discounts, etc.).

The revenue's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The revenue's Applied BioCode historically and in real time.

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Applied BioCode

All Key Metrics — Applied BioCode